Skip to main content

Table 2 The effect of the type of drug resistance or history of TB treatment on the culture conversion rate at month 6 of the two groups

From: Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

Indicators BDQ group (n = 102)   Non-BDQ group (n = 100)   p value
  Conversion Failed to conversion Conversion Failed to conversion  
Type of drug resistance (n, %)      
 RR 3 (100.0) 0 (0.0) 4 (80.0) 1 (20.0) 1.00
 MDR 65 (87.8) 9 (12.2) 50 (73.5) 18 (26.5) 0.03*
 XDR 22 (88.0) 3 (12.0) 18 (66.7) 9 (33.3) 0.07
History of TB treatment (n, %)      
 New cases 10 (90.9) 1 (9.1) 6 (75.0) 2 (25.0) 0.55
 One-time history of TB treatment 34 (91.9) 3 (8.1) 19 (76.0) 6 (24.0) 0.17
 Two-time history of TB treatment 27 (84.4) 5 (15.6) 31 (81.6) 7 (18.4) 0.76
 ≥ Three-time history of TB treatment 19 (86.4) 3 (13.6) 16 (55.2) 13 (44.8) 0.02*
 MDR/RR-TB (n = 77)   (n = 73)   
 New cases 7(100.0) 0(0.0) 5 (71.4) 2 (28.6) 0.46
 One-time history of TB treatment 30 (90.9) 3 (9.1) 15 (71.4) 6 (28.6) 0.06
 Two-time history of TB treatment 19 (86.4) 3 (13.6) 23 (88.5) 3 (11.5) 0.83
 ≥ Three-time history of TB treatment 13 (86.7) 2 (13.3) 11 (57.9) 8 (42.1) 0.13
 XDR-TB (n = 25)   (n = 27)   
 New cases 3 (75.0) 1 (25.0) 1 (100.0) 0 (0.0) 1.00
 One-time history of TB treatment 4 (100.0) 0 (0.0) 4 (100.0) 0 (0.0)
 Two-time history of TB treatment 8 (80.0) 2 (20.0) 8 (66.7) 4 (33.3) 0.65
 ≥ Three-time history of TB treatment 6 (85.7) 1 (14.3) 5 (50.0) 5 (50.0) 0.30
  1. TB tuberculosis, n number, RR rifampicin-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, BDQ bedaquiline
  2. * the differences had statistical significance (p < 0.05)